These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 4584157)

  • 1. Spironolactone and plasma cortisol.
    Dumlao JS; Kannan C; Krauss T; Brooks MH
    Clin Pharmacol Ther; 1973; 14(6):992-4. PubMed ID: 4584157
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours.
    Merkus FW; Overdiek JW; Cilissen J; Zuidema J
    Clin Exp Hypertens A; 1983; 5(2):239-48. PubMed ID: 6831747
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.
    Sadée W; Dagcioglu M; Schröder R
    J Pharmacol Exp Ther; 1973 Jun; 185(3):686-95. PubMed ID: 4712657
    [No Abstract]   [Full Text] [Related]  

  • 4. Enhancement by food of canrenone bioavailability from spironolactone.
    Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
    Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bioavailability studies of two spironolactone-preparations (author's transl)].
    Vergin H; Nuss U; Schwarzländer F; Strobel K; Weigand W; Hitzenberger G
    Arzneimittelforschung; 1981; 31(9):1498-503. PubMed ID: 7197963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
    Vergin H; Nuss U; Strobel K
    Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma cortisol assay. Interference by spironolactone.
    Lurie AO
    JAMA; 1970 Mar; 211(11):1851-2. PubMed ID: 5467115
    [No Abstract]   [Full Text] [Related]  

  • 8. [Comparative bioavailability of two forms of spironolactone. Rationalization applied to dosage (author's transl)].
    d'Athis P; Richard MO; de Lauture D; Rey E; Bouvier d'Yvoire M; Clement E; Olive G
    Therapie; 1981; 36(4):443-9. PubMed ID: 7292427
    [No Abstract]   [Full Text] [Related]  

  • 9. Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability.
    Karim A
    Drug Metab Rev; 1978; 8(1):151-88. PubMed ID: 363379
    [No Abstract]   [Full Text] [Related]  

  • 10. Interference in the measurement of plasma 11-hydroxycorticosteroids caused by spironolactone administration.
    Wood LC; Richards R; Ingbar SH
    N Engl J Med; 1970 Mar; 282(12):650-2. PubMed ID: 5417730
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of spironolactone on neonatal screening for congenital adrenal hyperplasia.
    Terai I; Yamano K; Ichihara N; Arai J; Kobayashi K
    Arch Dis Child Fetal Neonatal Ed; 1999 Nov; 81(3):F179-83. PubMed ID: 10525019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Eplerenone for treatment of heart failure].
    Yoshimura M
    Nihon Rinsho; 2007 May; 65 Suppl 5():153-8. PubMed ID: 17569313
    [No Abstract]   [Full Text] [Related]  

  • 13. [Comparative study of relative biovailability of several spironolactone formulations in a steady-state test (author's transl)].
    Rosenthal J; Jaeger H; Specker M
    Arzneimittelforschung; 1979; 29(9):1428-32. PubMed ID: 583254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites.
    Tidd MJ; Collins WT; Chamberlain J
    J Int Med Res; 1976; 4(2):86-95. PubMed ID: 1037443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone. II. Bioavailability.
    Karim A; Zagarella J; Hutsell TC; Chao A; Baltes BJ
    Clin Pharmacol Ther; 1976 Feb; 19(2):170-6. PubMed ID: 1261154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
    Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
    Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spironolactone metabolism in normal subjects and in patients with liver cirrhosis.
    Váradi A; Fehér T; Bodrogi L; Koref O
    Arzneimittelforschung; 1977; 27(8):1618-20. PubMed ID: 578759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cortisol and cortisone analysis in serum and plasma by atmospheric pressure photoionization tandem mass spectrometry.
    Kushnir MM; Neilson R; Roberts WL; Rockwood AL
    Clin Biochem; 2004 May; 37(5):357-62. PubMed ID: 15087250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Normoaldosterone spironolactone sensitive hypertension--a case report].
    Krysiak R; Okopień B; Herman ZS
    Pol Arch Med Wewn; 2005 Oct; 114(4):978-81. PubMed ID: 16789524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is canrenone the major metabolite of spironolactone?
    Merkus FW
    Clin Pharm; 1983; 2(3):209-10. PubMed ID: 6883952
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.